Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : TGEN - Targeted Genetics Corporation -- Ignore unavailable to you. Want to Upgrade?

To: JMarcus who wrote (210)	11/29/1999 12:31:00 PM
From: John B. Anderson	Read Replies (1) \| Respond to of 557

I agree with posters who have felt that if Avigen is worth a market cap 5 times that of TGEN, then maybe that means TGEN is undervalued. Ever since Cell Genesis was acquired by Genzyme, this "Genetic Technology" group has been moving up steadily. If one wants a position in this technology, one of the companies with credibility (and enough cash and partnerships) to be worth speculating on is TGEN. The fact that AVGN may have a breakthrough in using the AAV vector to cure the genetic cause of blood clotting deficiencies (said to have been 100% effective in dogs) means that companies that are working in this area (esp. using the AAV vector) are prime targets for acquisition....